VYGR News and Press, Voyager Therapeutics Inc. From 05/05/24

2024-05-05 08:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

LEXINGTON, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will present a broad set of data related to its TRACER™ capsid discovery platform and TRACER-driven...

LEXINGTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development can...

2024-03-16 15:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-13 13:11:39 ET Summary The company's strength lies in its TRACER capsids technology that can deliver therapeutic molecules to the brain, leading to multimillion-dollar deals with pharmaceutical giants, such as Novartis. Despite the risks and uncertainties, long-term invest...

2024-03-13 09:57:09 ET More on Voyager Therapeutics Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier Voyager Therapeutics GAAP EPS of $1.25 beats by $1.54, revenue of $90.06M beats by $69.42M Voyager Therapeutics Q4 2023 Earnings Pre...

LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer (CMO), effective March 25, 2024. Ferguson ...

2024-03-08 15:25:00 ET Summary Voyager Therapeutics, a drug delivery specialist focused on AAV vectors for gene therapies, has faced many challenges, including partners walking away from deals, disappointing data, and management changes. The company has recently gained momentum th...

- Company had approximately $431 million in pro-forma cash as of December 31, 2023, adjusted for $100 million consideration from Novartis agreements and $100 million public offering - - Strong cash position and anticipated milestones/reimbursements provide runway into 2027, potentially ...

SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...